Related Experiment Videos
Cardiotrophin-1 (CT-1): a novel hypertrophic and cardioprotective agent
1Department of Molecular Pathology, Windeyer Institute of Medical Sciences, University College London, London, UK.
Insights
Cardiotrophin-1 (CT-1), a cytokine, promotes cardiac cell survival and hypertrophy. Its survival effects involve the p42/p44 MAP kinase pathway, while hypertrophy involves Jak/STAT-3, suggesting potential cardio-protective applications.
Area of Science:
- Cardiovascular Biology
- Cell Signaling
- Cytokine Research
Background:
- Cardiotrophin-1 (CT-1) is an IL-6 family cytokine with known roles in cardiac myocyte hypertrophy.
- CT-1 also demonstrates cell survival-promoting effects in both cardiac and neuronal cells.
- Distinct signaling pathways mediate CT-1's survival and hypertrophic actions.
Purpose of the Study:
- To elucidate the specific signaling pathways responsible for CT-1's diverse cellular effects.
- To explore the potential of CT-1 as a therapeutic agent for cardiovascular protection.
- To investigate the differential involvement of MAP kinase and Jak/STAT pathways in CT-1 function.
Main Methods:
- Investigating CT-1's impact on cardiac and neuronal cell survival.
- Analyzing the role of the p42/p44 MAP kinase pathway in CT-1-mediated survival.
- Examining the involvement of the Jak/STAT-3 pathway in CT-1-induced hypertrophy.
Main Results:
- CT-1 promotes survival in cardiac and neuronal cells.
- p42/p44 MAP kinase activation is essential for CT-1's survival-promoting effects.
- CT-1's hypertrophic effect on cardiac cells is independent of p42/p44 MAP kinase and likely involves Jak/STAT-3 activation.
Conclusions:
- CT-1 exhibits dual roles in cardiac cells, promoting both survival and hypertrophy via distinct signaling pathways.
- The Jak/STAT-3 pathway is implicated in CT-1-induced cardiac hypertrophy.
- CT-1 holds promise as a cardio-protective agent, with potential for therapeutic development if hypertrophy can be selectively modulated.
Abstract:
Cardiotrophin-1 (CT-1) is a member of the IL-6 family of cytokines which was originally discovered as a factor which can induce hypertrophy of cardiac myocytes both in vitro and in vivo. Subsequently, CT-1 has been shown to have a wide variety of different effects on cardiac and non cardiac cells including the ability to stimulate the survival of both cardiac and neuronal cells. Interestingly, whilst activation of the p42/p44 MAP kinase pathway is necessary for the survival promoting effects of CT-1 in cardiac cells, it is not required for its hypertrophic effect which is likely to involve activation of the Jak/STAT-3 pathway. CT-1 may therefore be of use as a novel cardio-protective agent, particularly if its hypertrophic effect can be specifically inhibited.